RGNT Stock Summary and Trading Ideas (Regentis Biomaterials Ltd. | AMEX:RGNT)

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Regentis Biomaterials Ltd. trades on the AMEX stock market under the symbol RGNT.

As of October 13, 2026, RGNT stock price climbed to $1.64 with 18,523 million shares trading.

RGNT has a beta of 2.73, meaning it tends to be more sensitive to market movements. RGNT has a correlation of 0.05 to the broad based SPY ETF.

RGNT has a market cap of $11.52 million. This is considered a Sub-Micro Cap stock.

RGNT support price is $1.53 and resistance is $1.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNT shares will trade within this expected range on the day.